贝伐珠单抗联合福斯布雷塔布林治疗复发性卵巢癌:一项随机II期NRG肿瘤/妇科肿瘤组研究的总生存期和探索性分析
该研究为GOG-0186I随机II期试验的探索性事后分析,纳入107例复发性卵巢癌患者,随机接受贝伐珠单抗联合或不联合福斯布雷塔布林治疗。长期随访显示联合组中位无进展生存期7.6个月,单药组4.8个月(HR 0.74;90% CI 0.54-1.02),总生存期两组相似(25.2 vs 24.4个月,HR 0.85;90% CI 0.59-1.22;p=.461)。在肿瘤>5.7 cm亚组中联合治疗进展或死亡HR为0.55(90% CI 0.32-0.96;p=.075)。
要点
- 联合组中位无进展生存期7.6个月,单药组4.8个月,HR 0.74(90% CI 0.54-1.02)。
- 总生存期两组相似:联合组25.2个月 vs 单药组24.4个月,HR 0.85(90% CI 0.59-1.22;p=.461)。
- 肿瘤>5.7 cm亚组联合治疗进展或死亡HR 0.55(90% CI 0.32-0.96;p=.075)。
核心结论
- 未观察到显著生存获益,但肿瘤越大,联合福斯布雷塔布林相比单用贝伐珠单抗的进展或死亡HR降低趋势越明显,值得进一步研究。
研究设计与样本
- 随机II期试验GOG-0186I的探索性事后分析,纳入107例既往接受过至多3种方案的复发性卵巢癌患者。
- 患者随机接受贝伐珠单抗15 mg/kg体重联合或不联合静脉福斯布雷塔布林60 mg/m2体表面积,每21天一次,直至进展或不可耐受毒性。
主要发现
- 延长随访后,联合组中位无进展生存期7.6个月 vs 单药组4.8个月(HR 0.74;90% CI 0.54-1.02)。
- 总生存期联合组25.2个月 vs 单药组24.4个月(HR 0.85;90% CI 0.59-1.22;p=.461)。
- 81例可测量病灶患者中位肿瘤大小5.7 cm;≤5.7 cm亚组进展或死亡HR 0.77(90% CI 0.45-1.31)。
- 肿瘤>5.7 cm亚组(n=40)进展或死亡HR 0.55(90% CI 0.32-0.96;p=.075)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. METHODS: An exploratory, post-hoc analysis of the randomized phase II trial, Gynecologic Oncology Group-0186I, was performed. One hundred and seven patients with recurrent ovarian carcinoma, treated with up to 3 prior regimens, were randomized to bevacizumab 15 mg/kg body weight with or without intravenous fosbretabulin 60 mg/m2 body surface area every 21 days until progression or unacceptable toxicity. The primary analysis favored the combination (HR 0.69; 95% CI, 0.47-1.00; p = .049) [Monk BJ, et al. J Clin Oncol 2016;34:2279-86]. The Cox proportional hazards model was used to estimate the treatment effect in various subpopulations. RESULTS: With extended follow-up, the median PFS for bevacizumab plus fosbretabulin was 7.6 months as compared to 4.8 months with bevacizumab alone (HR 0.74; 90% CI, 0.54-1.02). Overall survival was similar in the experimental and control arms (25.2 vs 24.4 mos, respectively, HR 0.85; 90% CI, 0.59-1.22; p = .461). Eighty-one patients had measurable disease and median tumor size was 5.7 cm. In the ≤5.7 cm subgroup, the HR for progression or death was 0.77 (90% CI 0.45-1.31). Patients with tumors >5.7 cm (n = 40) had a HR for progression or death of 0.55; 90% CI, 0.32-0.96; p = .075). CONCLUSIONS: Although no significant survival benefit was observed, the trend showing a reduced HR for progression or death with increasing tumor size when fosbretabulin is added to bevacizumab compared to bevacizumab alone warrants further study.
引用
- Tewari KS, Sill MW, Coleman RL, et al. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020. PMID: 32723679. doi:10.1016/j.ygyno.2020.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。